Lung Cancer: Epidemiology, Risk Factors, Diagnosis, and Treatment An Analytical Reference Study
DOI:
https://doi.org/10.65405/2tc2k470الكلمات المفتاحية:
lung cancer, smoking, low-dose computed tomography, targeted therapy, immunotherapy.الملخص
Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death worldwide. This paper reviews the current epidemiological situation, risk factors, histological classification, early detection strategies, and recent therapeutic advances, with a focus on targeted therapy and immunotherapy. It concludes that tobacco control, early screening with low-dose computed tomography, and personalized treatment guided by molecular testing are the most important pillars for reducing the disease burden.
التنزيلات
المراجع
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
2. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024;93:102693. doi:10.1016/j.canep.2024.102693.
3. Global, regional, and national burden of tracheal, bronchus, and lung cancer in 2022: evidence from the GLOBOCAN study. PMC11675692.
4. Global Cancer Facts & Figures, 5th Edition. American Cancer Society; 2024.
5. Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer. 2012;131(12):2724-2732.
6. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 WHO classification of lung tumors. J Thorac Oncol. 2015;10(9):1243-1260.
7. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299-311.
8. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
9. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382:503-513.
10. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
11. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.
12. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-125.
13. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
15. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 1954;8(1):1-12.
16. Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tob Control. 1994;3:242-247.
17. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570.
18. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-180.
19. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for the 8th edition of the TNM classification. J Thorac Oncol. 2016;11(1):39-51.
20. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7:3.
21. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733-742.
22. World Health Organization. WHO Framework Convention on Tobacco Control. Geneva: WHO; 2003.
